MAS1L and Parkinson disease: Wilcoxon–Mann–Whitney test analysis revealed significantly higher serum levels of MasR-AAs in PD patients compared to controls (p  <  0.01; W  =  4020), while no significant difference was observed for AT2-AAs (p > 0.05; W  =  4921) (Figure 1).